Retroperitoneal Lymph Node Dissection in Treating Patients With Stage I-IIA Testicular Seminoma
Conditions: Lymphadenopathy; Stage I Testicular Seminoma; Stage II Testicular SeminomaInterventions: Other: Laboratory Biomarker Analysis; Procedure: Retroperitoneal Lymph Node DissectionSponsors: University of Southern California; National Cancer Institute (NCI)Recruiting - verified September 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2015 Category: Research Source Type: clinical trials
A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT
Condition: Metastatic SeminomaIntervention: Drug: Carboplatin AUC-10Sponsor: Barts & The London NHS TrustRecruiting - verified October 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 22, 2014 Category: Research Source Type: clinical trials
Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy
Conditions: Non-seminomatous Germ Cell Tumors; MetastasisInterventions: Other: K5-RGD PET; Other: FDGSponsor: Centre Francois BaclesseRecruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2014 Category: Research Source Type: clinical trials
Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy
Conditions: Non-seminomatous Germ Cell Tumors; MetastasisInterventions: Other: K5-RGD PET; Other: FDGSponsor: Centre Francois BaclesseNot yet recruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2014 Category: Research Source Type: clinical trials
Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy
Conditions: Non-seminomatous Germ Cell Tumors; MetastasisInterventions: Other: K5-RGD PET; Other: FDGSponsor: Centre Francois BaclesseRecruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2014 Category: Research Source Type: clinical trials
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
Conditions: Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Malignant Extragonadal Germ Cell Tumor; Malignant Extragonadal Non-Seminomatous Germ Cell Tumor; Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Ovarian Germ Cell Tumor; Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor; Stage IV Extragonadal Seminoma; Stage IV Ovarian Germ Cell TumorIntervention: Drug: palifosfamideSponsors: Indiana University School of Medicine; ZiopharmRecruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2013 Category: Research Source Type: clinical trials
A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT
Condition: Metastatic SeminomaIntervention: Drug: Carboplatin AUC-10Sponsor: Barts & The London NHS TrustRecruiting - verified October 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2012 Category: Research Source Type: clinical trials
